|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Chemocentryx, Inc. (CCXI) |
|
|
$51.99 0.00 (0.00%) as of 4:30 Wed 10/19
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
69,210,000 |
| Market
Cap: |
3.60(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$51.99 - $51.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ChemoCentryx is an integrated biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. Co. targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the U.S., Co. markets TAVNEOS® (avacopan) as an adjunctive treatment for adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis, and microscopic polyangiitis. Co. is also developing TAVNEOS for the treatment of severe Hidradenitis Suppurativa.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
217,623 |
| Total Sell Value |
$0 |
$0 |
$0 |
$10,849,434 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bekker Petrus |
Chief Medical Officer |
• – – |
2016-11-11 |
4 |
OE |
$6.00 |
$16,188 |
D/D |
2,698 |
56,292 |
|
- |
|
| Bekker Petrus |
Chief Medical Officer |
• – – |
2016-11-10 |
4 |
AS |
$8.00 |
$240,000 |
D/D |
(30,000) |
53,594 |
|
- |
|
| Bekker Petrus |
Chief Medical Officer |
• – – |
2016-11-10 |
4 |
OE |
$6.00 |
$180,000 |
D/D |
30,000 |
83,594 |
|
- |
|
| Bekker Petrus |
Chief Medical Officer |
• – – |
2016-11-09 |
4 |
AS |
$8.00 |
$5,072 |
D/D |
(634) |
53,594 |
|
- |
|
| Bekker Petrus |
Chief Medical Officer |
• – – |
2016-11-09 |
4 |
OE |
$6.00 |
$3,804 |
D/D |
634 |
54,228 |
|
- |
|
| Mckinnell Henry A |
Director |
– • – |
2016-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
31,306 |
31,306 |
|
- |
|
| Lucas Roger C |
Director |
– • – |
2016-11-01 |
4 |
AS |
$6.10 |
$24,411 |
D/D |
(4,000) |
70,822 |
|
- |
|
| Lucas Roger C |
Director |
– • – |
2016-09-01 |
4 |
AS |
$5.07 |
$20,262 |
D/D |
(4,000) |
74,822 |
|
- |
|
| Edwards Thomas A. |
Director |
– • – |
2016-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,767 |
98,744 |
|
- |
|
| Tyree James L |
Director |
– • – |
2016-05-23 |
4 |
AS |
$4.39 |
$24,337 |
D/D |
(5,544) |
20,575 |
|
- |
|
| Lucas Roger C |
Director |
– • – |
2016-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,795 |
78,822 |
|
- |
|
| Tyree James L |
Director |
– • – |
2016-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,795 |
26,119 |
|
- |
|
| Feczko Joseph M |
Director |
– • – |
2016-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,795 |
48,822 |
|
- |
|
| Parker Geoffrey M. |
Director |
– • – |
2016-05-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,795 |
25,309 |
|
- |
|
| Edwards Thomas A. |
Director |
– • – |
2016-05-17 |
4 |
B |
$4.05 |
$202,500 |
D/D |
50,000 |
91,977 |
2.39 |
- |
|
| Edwards Thomas A. |
Director |
– • – |
2016-05-16 |
4 |
B |
$4.05 |
$101,213 |
D/D |
25,000 |
41,977 |
2.39 |
- |
|
| Parker Geoffrey M. |
Director |
– • – |
2016-05-13 |
4 |
B |
$4.03 |
$161,388 |
I/I |
40,000 |
99,600 |
2.1 |
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-22 |
4 |
AS |
$4.06 |
$61,429 |
D/D |
(15,127) |
0 |
|
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-22 |
4 |
OE |
$2.00 |
$30,254 |
D/D |
15,127 |
15,127 |
|
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-21 |
4 |
AS |
$4.02 |
$42,726 |
D/D |
(10,637) |
0 |
|
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-21 |
4 |
OE |
$2.00 |
$21,274 |
D/D |
10,637 |
10,637 |
|
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-20 |
4 |
AS |
$4.10 |
$61,341 |
D/D |
(14,971) |
0 |
|
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-20 |
4 |
OE |
$2.00 |
$29,942 |
D/D |
14,971 |
14,971 |
|
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-19 |
4 |
AS |
$4.05 |
$24,826 |
D/D |
(6,134) |
0 |
|
- |
|
| Kanaya Susan M |
SVP, Finance, CFO and Sec. |
• – – |
2016-01-19 |
4 |
OE |
$2.00 |
$12,268 |
D/D |
6,134 |
6,134 |
|
- |
|
472 Records found
|
|
Page 16 of 19 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
